ArticleEukaryotic cell2008
Atf2 transcription factor binds to the APP1 promoter in Cryptococcus neoformans: stimulatory effect of diacylglycerol.
Article in Eukaryotic cell, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Antiphagocytic protein 1 increases the susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole.PloS one · 2019Article
- Fbp1-mediated ubiquitin-proteasome pathway controls Cryptococcus neoformans virulence by regulating fungal intracellular growth in macrophages.Infection and immunity · 2014Article
- Cryptococcus neoformans: historical curiosity to modern pathogen.Yeast (Chichester, England) · 2014Review
- Article
- Role of glucose in the expression of Cryptococcus neoformans antiphagocytic protein 1, App1.Eukaryotic cell · 2011Article
- Characterization of inositol phospho-sphingolipid-phospholipase C 1 (Isc1) in Cryptococcus neoformans reveals unique biochemical features.FEBS letters · 2011Article
- Lipid signalling in pathogenic fungi.Cellular microbiology · 2011Review
- Cryptococcus neoformans modulates extracellular killing by neutrophils.Frontiers in microbiology · 2011Article
- Sphingolipid signaling in fungal pathogens.Advances in experimental medicine and biology · 2010Review
- App1: an antiphagocytic protein that binds to complement receptors 3 and 2.Journal of immunology (Baltimore, Md. : 1950) · 2009Article
- Lipid signaling in pathogenic fungi.Annual review of microbiology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The fungus Cryptococcus neoformans is an environmental human pathogen which enters the lung via the respiratory tract and produces a unique protein, called antiphagocytic protein 1 (App1), that protects it from phagocytosis by macrophages. In previous studies, we proposed genetic evidences that transcription of APP1 is controlled by the enzymatic reaction catalyzed by inositol phosphorylceramide synthase 1 (Ipc1) via the production of diacylglycerol through the activating transcription factor 2 (Atf2). We investigated here the mechanism by which Atf2 binds to the APP1 promoter in vitro and in vivo. To this end, we produced Atf2 recombinant proteins (rAtf2) and found that rAtf2 binds to ATF cis-acting element present in the APP1 promoter. Indeed, mutation of two key nucleotides in the ATF consensus sequence abolishes the binding of rAtf2 to the APP1 promoter. Next, we produced C. neoformans strains with a hemagglutinin-tagged ATF2 gene and showed that endogenous Atf2 binds to APP1 promoter in vivo. Finally, by a novel DNA protein-binding precipitation assay, we showed that treatment with 1,2-dioctanoylglycerol positively increases binding of Atf2-APP1 promoter in vivo. These studies provide new insights into the molecular mechanism by which Atf2 regulates APP1 transcription in vivo with important implications for a better understanding of how C. neoformans escapes the phagocytic process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.